Due to the growing number of immunocompromised patients in recent years, the incidence of opportunistic fungal infections has been significantly increased. Candida krusei has emerged as a causative fungus of disseminated fungal infections, especially in susceptible patients. The intrinsic resistance of Candida krusei to fluconazole makes it important to exploit novel antifungal drugs against this yeast. As a worlding leading CRO in the field of drug discovery, Creative Biolabs now provides a comprehensive series of antifungal drug discovery services to facilitate your project. Here, we focus on drug development against Candida krusei.
Introduction to Candida Krusei
Candida kruse (C. kruse) is an emerging fungal nosocomial pathogen belonging to the Candida spp. It has been considered to be a facultative saprophy and is widely distributed in nature. C. kruse has been isolated from a large variety of natural habitats including the atmosphere, soil, silage, sewage, foods, fruits, beer, and wines. The infection of C. kruse is primarily found in the immunocompromised people, the patients with hematological malignancies, and those transplant recipients. Mortality rate caused by C. krusei fungemia is much higher than the more common C. albicans, which is reported to be 30–60%.
Fig.1 Scanning elecrronmtcrographs of three oral isolates of C krusei. (Samaranayake, 1994)
Pathogenesis of C. krusei
Candida spp. has been reported to have several virulence attributes, including the production of phospholipases and proteinases, adherence to host surfaces, and hyphae formation, which help the fungus escape from the host immune defenses. C. krusei grew with both the yeast and mycelial phases, in the infected tissues. However, the fungus typically showed less invasiveness than C. albicans or C. tropicalis. C. krusei did not penetrate the stratum corneum, while C. albicans generated extensive epithelial invasion and penetrated all the layers of the epithelium.
Antifungal Drugs Against C. krusei
C. krusei has been considered as a potentially multidrug-resistant (MDR) fungal pathogen because of its natural resistance combined with decreased susceptibility to both amphotericin B and flucytosine. It is urgent to develop novel drugs against C. krusei.
Antifungal Drug Discovery Services Against C. krusei at Creative Biolabs
Creative Biolabs is a recognized expert in fungal infection disease and antifungal drug discovery. Our scientists are committed to providing our customers with a comprehensive service package, which includes target identification and validation, Hit identification, Hit to lead, Lead optimization, and IND enabling. Our experienced scientists can assist you in preclinical drug through a variety of assays including:
You may also be interested in other fungi that may be implicated in candidiasis:
If you are interested in our antifungal drug discovery services, please do not hesitate to contact us for more details.
Reference
For Research Use Only.
